Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Nielsen, Torsten ^a,d   Wallden, Brett ^b   Schaper, Carl ^c   Ferree, Sean ^b   Liu, Shuzhen ^a   Gao, Dongxia ^a   Barry, Garrett ^a   Dowidar, Naeem ^b   Maysuria, Malini ^b   Storhoff, James ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b NanoString Technologies Inc   (United States)

^c Myraqa   (United States)

^d VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Analytical validation; Breast cancer; FFPE; Gene expression; NanoString; nCounter; PAM50; Prosigna; Reproducibility; ROR; Subtype

Indexed keywords

ANALYTICAL EQUIPMENT; ANALYTICAL PARAMETERS; ARTICLE; BIOASSAY; BREAST CANCER; BREAST TUMOR; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; COMPARATIVE STUDY; CONTROLLED STUDY; EXPERIMENTAL DESIGN; GENE; GENE EXPRESSION PROFILING; GENE SIGNATURE ASSAY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MEASUREMENT ACCURACY; PAM50 GENE; PREDICTIVE VALUE; QUALITY CONTROL; REPRODUCIBILITY; RISK ASSESSMENT; RISK OF RECURRENCE SCORE; RNA EXTRACTION; RNA INTERFERENCE; RNA ISOLATION; RNA PROCESSING; STATISTICAL ANALYSIS; VALIDATION STUDY; VALIDITY; VARIANCE COMPONENTS ANALYSIS;

BREAST NEOPLASMS; FEMALE; FORMALDEHYDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PARAFFIN EMBEDDING; PATHOLOGY, MOLECULAR; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RNA; TUMOR MARKERS, BIOLOGICAL; VALIDATION STUDIES AS TOPIC;

EID: 84897400979     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-177     Document Type: Article

References (43)

1. Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol 2012, 6(2):140-146. 10.1016/j.molonc.2012.01.010, 22356776.
2. Dietel M, Johrens K, Laffert M, Hummel M, Blaker H, Muller BM, Lehmann A, Denkert C, Heppner FL, Koch A, Sers C, Anagnostopoulos I. Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Ther 2013, 20(4):211-221. 10.1038/cgt.2013.13, 23492822.
3. Duffy MJ, Crown J. Companion Biomarkers: Paving the Pathway to Personalized Treatment for Cancer. Clin Chem 2013, 59(10):1447-1456. 10.1373/clinchem.2012.200477, 23656699.
4. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 2008, 21(Suppl 2):S8-S15.
5. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical Oncology, College of American Pathologists American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25(1):118-145. American Society of Clinical Oncology, College of American Pathologists.
6. Sholl LM, Xiao Y, Joshi V, Yeap BY, Cioffredi LA, Jackman DM, Lee C, Janne PA, Lindeman NI. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol 2010, 133(6):922-934. 10.1309/AJCPST1CTHZS3PSZ, 3156055, 20472851.
7. Weichert W, Schewe C, Lehmann A, Sers C, Denkert C, Budczies J, Stenzinger A, Joos H, Landt O, Heiser V, Rocken C, Dietel M. KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn 2010, 12(1):35-42. 10.2353/jmoldx.2010.090079, 2797716, 20007841.
8. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752. 10.1038/35021093, 10963602.
9. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351(27):2817-2826. 10.1056/NEJMoa041588, 15591335.
10. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347(25):1999-2009. 10.1056/NEJMoa021967, 12490681.
11. Arpino G, Generali D, Sapino A, Del Lucia M, Frassoldati A, De Laurentis M, Paolo P, Mustacchi G, Cazzaniga M, De Placido S, Conte P, Cappelletti M, Zanoni V, Antonelli A, Martinotti M, Puglisi F, Berruti A, Bottini A, Dogliotti L. Gene expression profiling in breast cancer: a clinical perspective. Breast 2013, 22(2):109-120. 10.1016/j.breast.2013.01.016, 23462680.
12. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC, American Society of Clinical Oncology American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25(33):5287-5312. 10.1200/JCO.2007.14.2364, 17954709, American Society of Clinical Oncology.
13. Zujewski JA, Kamin L. Trial assessing individualized options for treatment for breast cancer: the TAILORx trial. Future Oncol 2008, 4(5):603-610. 10.2217/14796694.4.5.603, 18922117.
14. Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008, 26(5):729-735. 10.1200/JCO.2007.14.3222, 18258980.
15. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27(8):1160-1167. 10.1200/JCO.2008.18.1370, 2667820, 19204204.
16. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, Cheang MC, Mardis ER, Perou CM, Bernard PS, Ellis MJ. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010, 16(21):5222-5232. 10.1158/1078-0432.CCR-10-1282, 2970720, 20837693.
17. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, Fell HP, Ferree S, George RD, Grogan T, James JJ, Maysuria M, Mitton JD, Oliveri P, Osborn JL, Peng T, Ratcliffe AL, Webster PJ, Davidson EH, Hood L, Dimitrov K. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008, 26(3):317-325. 10.1038/nbt1385, 18278033.
18. Reis PP, Waldron L, Goswami RS, Xu W, Xuan Y, Perez-Ordonez B, Gullane P, Irish J, Jurisica I, Kamel-Reid S. mRNA transcript quantification in archival samples using multiplexed, color-coded probes. BMC Biotechnol 2011, 11:46-6750. 11-46, 10.1186/1472-6750-11-46, 3103428, 21549012.
19. Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW, Ferree S, Storhoff J, Schaper C, Cuzick J. Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy. J Clin Oncol 2013, 31(22):2783-2790. 10.1200/JCO.2012.46.1558, 23816962.
20. Gnant M, Filipits M, Mlineritsch B, Dubsky P, Jakesz R, Kwasny W, Fitzal F, Rudas M, Knauer M, Singer C, Greil R, Ferree S, Storhoff J, Cowens J, Schaper C, Liu S, Nielsen T. Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with ER + early breast cancer (EBC): An ABCSG study [abstract]. Cancer Res 2012, 72(24):P2-10-02.
21. Gnant M, Filipits M, Dubsky P, Rudas M, Balic M, Greil R, Ferree S, Cowens J, Schaper C, Nielsen T. 53O_PR Predicting risk for late metastasis: The PAM50 risk of recurrence (ROR) score after 5 years of endocrine therapy in postmenopausal women with HR + early breast cancer: A study on 1,478 patients from the ABCSG-8 trial [abstract]. Ann Oncol 2013, 24(3):29. doi:10.1093/annonc/mdt084.1.
22. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009, 101(21):1446-1452. 10.1093/jnci/djp335, 2782246, 19815849.
23. Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, Dotson WD, Douglas MP, Berg AO, EGAPP Working Group The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 2009, 11(1):3-14. 10.1097/GIM.0b013e318184137c, 2743609, 18813139, EGAPP Working Group.
24. Gnant M, Dowsett M, Filipits M, Lopez-Knowles E, Greil R, Balic M, Cowens J, Nielsen T, Shaper C, Sestak I, Fesl C, Cuzick J. Identifying clinically relevant prognostic subgroups in node-positive postmenopausal HR + early breast cancer patients treated with endocrine therapy: A combined analysis of 2,485 patients from ABCSG-8 and ATAC using the PAM50 risk of recurrence (ROR) score and intrinsic subtype [abstract]. J Clin Oncol 2013, 31:506.
25. Tholen D, Kallner A, Kennedy J, Krouwer J, Meier K. Clinical and Laboratory Standards Institute (CLSI). Evaluation of precision performance of quantitative measurement methods; approved guideline - second edition. CLSI document EP05-A2. 950 west valley road, suite 2500 2004, Wayne, PA, USA: CLSI.
26. NanoString Technologies Inc Prosigna™ Breast Cancer Prognostic Gene Signature Assay [Package Insert] 2013, Seattle, WA: NanoString Technologies, Inc, NanoString Technologies Inc.
27. Majidzadeh-A K, Esmaeili R, Abdoli N. TFRC and ACTB as the best reference genes to quantify Urokinase Plasminogen Activator in breast cancer. BMC Res Notes 2011, 4:215-0500. 4-215, 10.1186/1756-0500-4-215, 3141519, 21702980.
28. Szabo A, Perou CM, Karaca M, Perreard L, Palais R, Quackenbush JF, Bernard PS. Statistical modeling for selecting housekeeper genes. Genome Biol 2004, 5(8):R59. 10.1186/gb-2004-5-8-r59, 507884, 15287981.
29. Baker SC, Bauer SR, Beyer RP, Brenton JD, Bromley B, Burrill J, Causton H, Conley MP, Elespuru R, Fero M, Foy C, Fuscoe J, Gao X, Gerhold DL, Gilles P, Goodsaid F, Guo X, Hackett J, Hockett RD, Ikonomi P, Irizarry RA, Kawasaki ES, Kaysser-Kranich T, Kerr K, Kiser G, Koch WH, Lee KY, Liu C, Liu ZL, Lucas A, Manohar CF, Miyada G, Modrusan Z, Parkes H, Puri RK, Reid L, Ryder TB, Salit M, Samaha RR, Scherf U, Sendera TJ, Setterquist RA, Shi L, Shippy R, Soriano JV, Wagar EA, Warrington JA, Williams M, Wilmer F, Wilson M, Wolber PK, Wu X, Zadro R, External RNA Controls Consortium The External RNA Controls Consortium: a progress report. Nat Methods 2005, 2(10):731-734. 10.1038/nmeth1005-731, 16179916, External RNA Controls Consortium.
30. Warrington J, Corbisier P, Feilotter H, Hackett J, Reid L, Salit M, Wagar E, Williams P, Wolber P. Clinical and Laboratory Standards Institute (CLSI). Use of External RNA Controls in Gene Expression Assays; Approved Guideline. CLSI Document MM16-A. 940 west valley road, suite 1400 2006, Wayne, PA, USA: CLSI.
31. Berger R, Hsu J. Bioequivalence trials, intersection-union tests and equivalence confidence sets. Stat Sci 1996, 11:283-319.
32. Cronin M, Sangli C, Liu ML, Pho M, Dutta D, Nguyen A, Jeong J, Wu J, Langone KC, Watson D. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem 2007, 53(6):1084-1091. 10.1373/clinchem.2006.076497, 17463177.
33. Nuyten DS, Hastie T, Chi JT, Chang HY, van de Vijver MJ. Combining biological gene expression signatures in predicting outcome in breast cancer: An alternative to supervised classification. Eur J Cancer 2008, 44(15):2319-2329. 10.1016/j.ejca.2008.07.015, 3756930, 18715778.
34. Chia SK, Bramwell VH, Tu D, Shepherd LE, Jiang S, Vickery T, Mardis E, Leung S, Ung K, Pritchard KI, Parker JS, Bernard PS, Perou CM, Ellis MJ, Nielsen TO. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res 2012, 18(16):4465-4472. 10.1158/1078-0432.CCR-12-0286, 3743663, 22711706.
35. Cheang MC, Voduc KD, Tu D, Jiang S, Leung S, Chia SK, Shepherd LE, Levine MN, Pritchard KI, Davies S, Stijleman IJ, Davis C, Ebbert MT, Parker JS, Ellis MJ, Bernard PS, Perou CM, Nielsen TO. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clin Cancer Res 2012, 18(8):2402-2412. 10.1158/1078-0432.CCR-11-2956, 3743660, 22351696.
36. Jorgensen C, Nielsen T, Bjerre K, Liu S, Wallden B, Balslev E, Nielsen D, Ejlertsen B. PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients. Acta Oncol 2013,
37. Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Muller V, Janicke F, Schmidt M, Kolbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M, EP Investigators A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 2011, 17(18):6012-6020. 10.1158/1078-0432.CCR-11-0926, 21807638, EP Investigators.
38. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?. Genet Med 2009, 11(1):66-73. 2743614, 19125125, Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.
39. Kronenwett R, Bohmann K, Prinzler J, Sinn BV, Haufe F, Roth C, Averdick M, Ropers T, Windbergs C, Brase JC, Weber KE, Fisch K, Muller BM, Schmidt M, Filipits M, Dubsky P, Petry C, Dietel M, Denkert C. Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test. BMC Cancer 2012, 12:456-2407. 12-456, 10.1186/1471-2407-12-456, 3534340, 23039280.
40. Elloumi F, Hu Z, Li Y, Parker JS, Gulley ML, Amos KD, Troester MA. Systematic bias in genomic classification due to contaminating non-neoplastic tissue in breast tumor samples. BMC Med Genomics 2011, 4(54):8794-4-54.
41. Mee BC, Carroll P, Donatello S, Connolly E, Griffin M, Dunne B, Burke L, Flavin R, Rizkalla H, Ryan C, Hayes B, D'Adhemar C, Banville N, Faheem N, Muldoon C, Gaffney EF. Maintaining Breast Cancer Specimen Integrity and Individual or Simultaneous Extraction of Quality DNA, RNA, and Proteins from Allprotect-Stabilized and Nonstabilized Tissue Samples. Biopreserv Biobank 2011, 9(4):389-398. 10.1089/bio.2011.0034, 3558729, 23386926.
42. Graham K, Ge X, De Las MA, Tripathi A, Rosenberg CL. Gene expression profiles of estrogen receptor-positive and estrogen receptor-negative breast cancers are detectable in histologically normal breast epithelium. Clin Cancer Res 2011, 17(2):236-246. 10.1158/1078-0432.CCR-10-1369, 3059257, 21059815.
43. Clare S, Pardo I, Mathieson T, Lillemoe H, Blosser R, Choi M, Sauder C, Doxey D, Badve S, Storniolo A, Atale R, Radovich M. " Normal" tissue adjacent to breast cancer is not normal [abstract]. Cancer Res 2012, 72(24 Suppl):P1-03-02.